Details for New Drug Application (NDA): 217575
✉ Email this page to a colleague
NDA 217575 describes NOREPINEPHRINE BITARTRATE, which is a drug marketed by Amneal, Baxter Hlthcare Corp, Breckenridge, Caplin, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Meitheal, Metrics Pharm, Mylan Labs Ltd, Rising, Sandoz, Sun Pharm, Zydus Pharms, Inforlife, and Long Grove Pharms, and is included in eighteen NDAs. It is available from twenty suppliers. There are eight patents protecting this drug. Additional details are available on the NOREPINEPHRINE BITARTRATE profile page.
The generic ingredient in NOREPINEPHRINE BITARTRATE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
The generic ingredient in NOREPINEPHRINE BITARTRATE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
Summary for 217575
| Tradename: | NOREPINEPHRINE BITARTRATE |
| Applicant: | Caplin |
| Ingredient: | norepinephrine bitartrate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 217575
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NOREPINEPHRINE BITARTRATE | norepinephrine bitartrate | INJECTABLE;INJECTION | 217575 | ANDA | Caplin Steriles Limited | 65145-133 | 65145-133-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (65145-133-10) / 4 mL in 1 VIAL, SINGLE-DOSE (65145-133-01) |
| NOREPINEPHRINE BITARTRATE | norepinephrine bitartrate | INJECTABLE;INJECTION | 217575 | ANDA | BE Pharmaceuticals Inc. | 71839-143 | 71839-143-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (71839-143-10) / 4 mL in 1 VIAL, SINGLE-DOSE (71839-143-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1MG BASE/ML | ||||
| Approval Date: | Sep 15, 2023 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
